BeiGene Ltd (NAS:BGNE)
$ 205.75 -9.25 (-4.3%) Market Cap: 23.54 Bil Enterprise Value: 22.24 Bil PE Ratio: 0 PB Ratio: 6.36 GF Score: 81/100

Beigene Ltd at Morgan Stanley Global Healthcare Conference Transcript

Sep 14, 2022 / 01:10PM GMT
Release Date Price: $154.25 (-5.29%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

So perfect. Good morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Really pleased to have you here, the team from BeiGene with me just quickly before we get going, I need to read a short disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.

So pleased to have Angus Grant, who runs Business Development, Ed BeiGene; and Mark Lanasa, who is the CMO. And so I thought a nice place to just start would be I think everybody is familiar with BeiGene from your focus in China, but also now much more familiar with the fact that you're launching products globally and making real inroads here in the U.S. as well but I think there are a couple of sort of strategic pillars that you have as a company that gives you some advantages, especially around the network that you've

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot